



JRW

Patent
Attorney's Docket No. 1032469-000007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Sam T. LINDHOLM et al.) Group Art Unit: 1647
Application No.: 10/759,244.) Examiner: D. Romeo
Filed: January 20, 2004) Confirmation No.: 7086
For: OSTEOREGENIC DEVICE AND A)
METHOD FOR PREPARING THE)
DEVICE)

COMMUNICATION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants would like to thank Examiner Romeo for the telephone conference with Applicant's representative of December 18, 2006 regarding the following. In the Notice of Allowance issued October 3, 2006 (copy attached), the Examiner attached a Form PTO-1449, originally filed with an Information Disclosure Statement in the present application on August 2, 2004. The Examiner indicated that certain references cited in the Information Disclosure Statement failed to fully comply with 37 CFR 1.98(a)(s), which requires a legible copy of each cited foreign patent document and each non-patent literature publication.

Applicants assert that the references cited in the Information Disclosure Statement filed on August 2, 2004 in the present application fully comply with 37 CFR 1.98(a)(s), as they were cited and placed in the record in parent application Serial No. 09/125,963 on September 26, 2003. A full, complete copy of the

Information Disclosure Statement filed in the parent application on September 26, 2003 is attached, along with a copy of the stamped postcard showing receipt by the U.S. Patent and Trademark Office. Applicants also submit herewith copies of the cited references for the Examiner's convenience as he requested.


Per the telephone call with the Examiner of December 18, 2006, Applicant request that the Examiner acknowledge he has considered the attached references on behalf of the present application.

Applicants believe that a fee is not required for this submission, however, in the event a fee is necessary the Commissioner is hereby authorized to charge Deposit Account No. 02-4800, such fee.

Respectfully submitted,

Date: December 19, 2006

By:


Deborah H. Yellin
Registration No. 45,904

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Patent
Attorney's Docket No. 032469-001



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

LINDHOLM *et al.*

Application No.: 09/125,963

Filed: November 24, 1998

For: OSTEOGENIC DEVICE AND A
METHOD FOR PREPARING THE
DEVICE

) Group Art Unit: 1647

) Examiner: David S. Romeo

) Confirmation No.: 8371

)

**INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.


No additional fee for submission of an IDS is required.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: September 26, 2003

By: 
Deborah H. Yellin
Registration No. 45,904

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

9-26-03 CR

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

LINDHOLM *et al.*

Application No.: 09/125,963

Filed: November 24, 1998

For: OSTEOREGENIC DEVICE AND A
METHOD FOR PREPARING THE
DEVICE



Group Art Unit: 1647

Examiner: David S. Romeo

Confirmation No.: 8371

FOURTH INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, LINDHOLM et al. hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b) no fee or statement is required.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: September 26, 2003

By: Deborah H. Yellin
Deborah H. Yellin
Registration No. 45,904

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

9-26-03 CDR

(05/03)

Substitute for forms 1449A/PTO & 1449B/PTO

ATTORNEY'S DKT No.
032469-001APPLICATION NO.
09/125,963FOURTH INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Sam T. LINDHOLM et al.FILING DATE
November 24, 1998GROUP
1647

DEC 19 2006

U.S. PATENT DOCUMENTS			
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document
	4,975,527		KOEZUKA et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation Yes No
	WO 94/26322		PCT	11-24-1994	
	WO 95/24474		PCT	09-14-1995	
	WO 95/33830		PCT	12-14-1995	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	AABOE, M., et al., "Healing of experimentally created defects: a review," BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY (1995), pp. 312-318, vol. 33, Churchill Livingstone, Edinburgh, Scotland.
	BODEN, S.D. et al., "Video-Assisted Lateral Intertransverse Process Arthrodesis," SPINE (1996), pp. 2689-2697, vol. 21, Lippincott Williams & Wilkins, Hagerstown, MD.
	BOSTROM, M., et al., "Use of Bone Morphogenetic Protein-2 in the Rabbit Ulnar Nonunion Model," CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (1996), pp. 272-282, no. 327, Lippincott Williams & Wilkins, Philadelphia, PA.
	CLEMENT, J.H., et al., "Bone morphogenetic protein 2 in the early development of <i>Xenopus laevis</i> ," MECHANISMS OF DEVELOPMENT (1995), pp. 357-370, vol. 52, Elsevier Science, Limerick, Ireland.
	COOK, S.D., et al., "Recombinant Human Bone Morphogenetic Protein-7 Induces Healing in a Canine Long-Bone Segmental Defect Model," CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (1994), pp. 302-312, no. 301, J.B. Lippincott, Philadelphia, PA.
	COOK, S.D., et al., "The Effect of Recombinant Human Osteogenic Protein-1 on Healing of Large Segmental Bone Defects," THE JOURNAL OF BONE AND JOINT SURGERY, (1994), pp. 827-838, vol. 76-A, Amer. Vol., Boston, MA.
	COOK, S.D., et al., "In Vivo Evaluation of Recombinant Human Osteogenic Protein (rhOP-1) Implants As a Bone Graft Substitute for Spinal Fusions," SPINE (1994), pp. 1655-1663, vol. 19, Lippincott Williams & Wilkins, Hagerstown, MD.
	COOK, S.D., et al., "Effect of Recombinant Human Osteogenic Protein-1 on Healing of Segmental Defects in Non-Human Primates," BOSTON JOURNAL OF BONE AND JOINT SURGERY, (1995), pp. 734-750, American ed. 77(5), Boston, MA.
	COOK, S.D., et al., "Osteogenic Protein-1," CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (1996), pp. 29-38, no. 324, JB Lippincott, Philadelphia, PA.
	DUDLEY, A.T., et al., "A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye," GENES & DEVELOPMENT (1995), pp. 2795-2807, vol. 9, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
	EHRNBERG, A., et al., "Comparison of Demineralized Allogeneic Bone Matrix Grafting (the Urist Procedure) and the Ilizarov Procedure in Large Diaphyseal Defects in Sheep," THE JOURNAL OF BONE AND JOINT SURGERY, (1993), pp. 438-447, vol. 11, Orthopaedic Research Society, American Ed. Journal of Bone and Joint Surgery, Boston, MA.
	EINHORN, T.A., et al., "The Healing of Segmental Bone Defects Induced by Demineralized Bone Matrix," THE JOURNAL OF BONE AND JOINT SURGERY (1984), pp. 274-279, vol. 66-A, The Journal of Bone and Joint Surgery, Boston, MA.
	FANG, J., et al., "Stimulation of new bone formation by direct transfer of osteogenic plasmid genes," PROC. NATL. ACAD. SCI. (1996), pp. 5753-5758, vol. 93 (USA), National Academy of Sciences, Washington, DC.
	FISCHGRUND, J.S., et al., "Augmentation of Autograft Using rhBMP-2 and Different Carrier Media in the Canine Spinal Fusion Model," JOURNAL OF SPINAL DISORDERS (1996), pp. 467-472, vol. 10, No. 6, Lippincott Williams & Wilkins, Hagerstown, MD.
	GAO, T.J., et al., "Microscopic evaluation of bone-implant contact between hydroxyapatite, bioactive glass and tricalcium phosphate implanted in sheep diaphyseal defects," BIOMATERIALS (1995), pp. 1175-1179, vol. 16, Oxford, England.
	GAO, T.J., et al., "Enhanced Healing of Segmental Tibial Defects in Sheep by a Composite Bone Substitute Comprised of Tricalcium Phosphate Cylinder, Bone Morphogenetic Protein and Type IV Collagen," JOURNAL OF BIOMEDICAL MATERIALS RESEARCH (1996), vol. 32, Interscience, Wiley, Hoboken, NJ.
	GAO, T.J., et al., "A coral composite implant containing bone morphogenetic protein repairs a segmental tibial defect in sheep: mechanics and immune assay," INTERNATIONAL ORTHOPAEDICS., German Ceramics Society, Cologne, Germany.
	GAO, T.J., et al., "Comparative Study on Potential of Natural Coral and Tricalcium Phosphate Cylinders in Healing a Segmental Diaphyseal Defect in Sheep," BIOCERAMICS, pp. 199-204, vol. 8, German Ceramics Society, Cologne, Germany.
	GAO, T.J., et al., "Composite of Bone Morphogenetic Protein (BMP) and Type IV Collagen, Coral-Derived Coral Hydroxyapatite and Tricalcium Phosphate Ceramics," INTERNATIONAL ORTHOPAEDICS (ACCEPTED), Springer Verlag, Berlin, Germany.

Substitute for forms 1449A/PTO & 1449B/PTO	ATTORNEY'S DKT NO. 032469-001	APPLICATION NO. 09/125,963
FOURTH INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Sam T. LINDHOLM <i>et al.</i>
		FILING DATE November 24, 1998
		GROUP 1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	GAO, T.J., et al., "Bone Inductive Potential and Dose-Dependent Response of Bovine Bone Morphogenetic Protein Combined with Type IV Collagen Carrier," ANNALES CHIRURGIAE ET GYNAECOLOGIAE (1993), pp. 77-84, vol. 207, University of Tampere, Finland, University of Helsinki, Finland.
	GERHART, T.N., et al., "Healing Segmental Femoral Defects in Sheep Using Recombinant Human Bone Morphogenetic Protein," CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (1993), pp. 317-326, no. 293, J.B. Lippincott Company, Philadelphia, PA.
	HECKMAN, J.D., et al., "The Use of Bone Morphogenetic Protein in the Treatment of Non-Union in a Canine Model," THE JOURNAL OF BONE AND JOINT SURGERY (1991), pp. 750-764, vol. 73-A, The Journal of Bone and Joint Surgery, American Volume, Boston, MA.
	HELM, G.A., et al., "Utilization of type I collagen gel, demineralized bone matrix, and bone morphogenetic protein-2 to enhance autologous one lumbar spinal fusion," J. NEUROSURGERY. (1997), pp. 93-100, vol. 86, Charlottesville, VA.
	HOGAN, B.L.M., "Bone morphogenetic proteins: multifunctional regulators of vertebrate development," GENES & DEVELOPMENT (1996), pp. 1580-1594, vol. 10, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
	HOLLIGER, E.H., et al., "Morphology of the Lumbar Intertransverse Process Fusion Mass in the Rabbit Model: A Comparison Between Two Bone Graft Materials — rhBMP-2 and Autograft," JOURNAL OF SPINAL DISORDERS (1996), pp. 125-128, vol. 9, Lippincott Williams & Wilkins, Hagerstown, MD.
	HOLLINGER, J. & LEONG, K., "Poly(α -hydroxy acids): carriers for bone morphogenetic proteins," BIOMATERIALS (1996), pp. 187-194, vol. 17, Elsevier Science Limited, Butterworth-Heinemann, Oxford, England.
	HOTZ, G. & HARR, G., "Bone substitute with osteoinductive biomaterials – current and future clinical applications," INT. J. ORAL MAXILLOFAC. SURG. (1994), pp. 413-417, vol. 23, Munksgaard, Copenhagen, Denmark
	HU, Y.Y., "Experimental studies on reconstituted xenograft and its clinical application," Chinese Journal of Surgery, Vol. 31, no. 12, pp. 709-713, Zhonghua yi xue hui, Wai ke xue hui, Beijing, China.
	JOHNSON, E.E. & URIST, M.R., "Distal Metaphyseal Tibial Nonunions Associated with Significant Bowing Deformity and Cortical Bone Loss: Treatment with Human Bone Morphogenetic Protein (h-BMP) and Internal Fixation," (1989), pp. 613-620, vol. 63, Nippon Seikeigeka Gakkai Zasshi, Japan.
	JOHNSON, E.E., et al., "Repair of Segmental Defects of the Tibia with Cancellous Bone Grafts Augmented with Human Bone Morphogenetic Protein," CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (1988), pp. 249-257, no. 236, JB Lippincott, Philadelphia, PA.
	JOHNSON, E.E., et al., "Bone Morphogenetic Protein Augmentation Grafting of Resistant Femoral Nonunions," CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (1988), pp. 257-265, no. 230, JB Lippincott, Philadelphia, PA.
	JOHNSON, E.E., et al., "Autogeneic Cancellous Bone Grafts in Extensive Segmental Ulnar Defects in Dogs," CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (1989), pp. 254-265, no. 243, JB Lippincott, Philadelphia, PA.
	KATO, F., "Experimental study of chemical spinal fusion in the rabbit by means of bone morphogenetic protein," (1990), PubMed 2380596, Nippon Seikeigeka Gakkai Zasshi, Japan.
	KUBOKI, Y., et al., "Two Distinctive BMP-Carriers Induce Zonal Chondrogenesis and Membranous Ossification, Respectively; Geometrical Factors of Matrices for Cell-Differentiation," CONNECTIVE TISSUE RESEARCH (1995), pp. 219-226, vol. 32, Taylor & Francis, Philadelphia, PA.
	LEE, S.C., et al., "Healing of large segmental defects in rat femurs is aided by RhBMP-2 in PLGA matrix," JOURNAL OF BIOMEDICAL MATERIALS RESEARCH (1994), pp. 1149-1156, vol. 28, Wiley Interscience, Hoboken, NJ.
	LINDE, A. and HEDNER, E., "Recombinant Bone Morphogenetic Protein-2 Enhances Bone Healing, Guided by Osteopromotive e-PTFE Membranes: An Experimental Study in Rats," CALCIFIED TISSUE INT. (1995), pp. 549-553, vol. 56, Springer-Verlag, NY.
	LINDHOLM, T.S., et al., "Response of Bone Marrow Stroma Cells to Demineralized Cortical Bone Matrix in Experimental Spinal Fusion in Rabbits," CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (1988), pp. 296-302, no. 230, JB Lippincott, Philadelphia, PA.
	LINDHOLM, T.C., et al., "Bone Morphogenetic Proteins Regenerating Skull and Maxillo-Mandibular Defects," BONE MORPHOGENETIC PROTEINS (1996), pp. 149-155, R.G. Landes Company, Austin, TX.
	LINDHOLM, T.S. and GAO, T.J., "Functional Carriers for Bone Morphogenetic Proteins," ANNALES CHIRURGIAE ET GYNAECOLOGIAE Supplementum, (1993), pp. 3-12, vol. 82, University of Helsinki, Helsinki, Finland.
	LOVELL, T.P., et al., "Augmentation of Spinal Fusion With Bone Morphogenetic Protein in Dogs," CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (1989), pp. 266-274, no. 243, JB Lippincott, Philadelphia, PA.
	MIYAMOTO, S. & TAKAOKA, K., "Bone Induction and Bone Repair by Composites of Bone Morphogenetic Protein and Biodegradable Synthetic Polymers," ANNALES CHIRURGIAE ET GYNAECOLOGIAE Supplement. 69-76, vol. 82, University of Helsinki, Helsinki, Finland.
	MUSCHLER, G.F., et al., "Evaluation of Human Bone Morphogenetic Protein 2 in a Canine Spinal Fusion Model," CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (1994), pp. 229-240, no. 308, J.B. Lippincott Company, Philadelphia, PA.
	NILSSON, O.S., et al., "Bone Repair Induced by Bone Morphogenetic Protein in Ulnar Defects in Dogs," THE JOURNAL OF BONE AND JOINT SURGERY, British Volume, (1986), pp. 635-642, vol. 68-B, London, UK.

Substitute for forms 1449A/PTO & 1449B/PTO		ATTORNEY'S DKT NO. 032469-001	APPLICATION NO. 09/125,963
FOURTH INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Sam T. LINDHOLM <i>et al.</i>	
		FILING DATE November 24, 1998	GROUP 1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	ODA, S., et al., "Ectopic bone induction in recombinant human bone morphogenetic protein-2 (rhBMP-2) combined with biphasic calcium phosphate (BCP)," (1996), <i>The Journal of Stomatological Society, Japan</i>
	ONO, I., et al., "Promotion of the Osteogenic Activity of Recombinant Human Bone Morphogenetic Protein by Prostaglandin E ₁ ," <i>BONE</i> (1996), pp. 581-588, vol. 19, Elsevier Science Inc., NY.
	PANGANIBAN, G.E.F., et al., "Biochemical Characterization of the <i>Drosophila dpp</i> Protein, a Member of the Transforming Growth Factor β Family of Growth Factors," <i>MOLECULAR AND CELLULAR BIOLOGY</i> (1990), pp. 2669-2677, vol. 10, American Society for Microbiology, Washington, DC.
	PETIT, J.C. & RIPAMONTI, U., "Tissue Segregation Enhances Calvarial Osteogenesis in Adult Primates," <i>THE JOURNAL OF CRANIOFACIAL SURGERY</i> (1994), pp. 34-43, vol. 5, Little, Brown & Co., Boston, MA.
	RAGNI, P. & LINDHOLM T.S., "Interaction of Allogeneic Demineralized Bone Matrix and Porous Hydroxyapatite Bioceramics in Lumbar Interbody Fusion in Rabbits," <i>CLINICAL ORTHOPAEDICS AND RELATED RESEARCH</i> (1991), pp. 292-299, no. 272, JB Lippincott, Philadelphia, PA.
	RAGNI, P., et al., "Spinal Fusion Induced by Porous Hydroxyapatite Blocks (HA)," pp. 133-144, <i>Italian Journal of Orthopaedics & Traumatology</i> , Bologna, Italy.
	RAGNI, P.C. & LINDHOLM, T.S., "Bone Formation and Static Changes in the Thoracic Spine at Uni- or Bilateral Experimental Spondylodesis with Demineralized Bone Matrix (DBM)," pp. 237-252, <i>Italian Journal of Orthopaedics & Traumatology</i> , Bologna, Italy.
	RILEY, E.H., et al., "Bone Morphogenetic Protein-2," <i>CLINICAL ORTHOPAEDICS AND RELATED RESEARCH</i> (1996), pp. 39-46, no. 324, JB Lippincott, Philadelphia, PA.
	SAILER, H.F. & KOLB, E., "Application of purified bone morphogenetic protein (BMP) preparations in crano-maxillo-facial surgery," <i>JOURNAL OF CRANIO-MAXILLO-FACIAL SURGERY</i> (1994), pp. 191-199, vol. 22, Churchill Livingstone, Edinburgh, Scotland.
	SAILER, H.F. & KOLB, E., "Application of purified bone morphogenetic protein (BMP) in crano-maxillo-facial surgery," <i>JOURNAL OF CRANIO-MAXILLO-FACIAL SURGERY</i> (1994), pp. 2-11, vol. 22, Churchill Livingstone, Edinburgh, Scotland.
	SAMPATH, T.K. & REDDI, A.H., "Homology of bone-inductive proteins from human, monkey, bovine, and rat extracellular matrix," <i>PROC. NATL. ACAD. SCI. USA</i> (1983), pp. 6591-6595, vol. 80, National Academy of Sciences, Washington, DC.
	SAMPATH, T.K., et al., " <i>Drosophila</i> transforming growth factor β superfamily proteins induce endochondral bone formation in mammals," <i>PROC. NATL. ACAD. SCI. USA</i> (1993), pp. 6004-6008, vol. 90, National Academy of Sciences, Washington, DC.
	SANDHU, H.S., et al., "Evaluation of rhBMP-2 With an OPLA Carrier in a Canine Posterolateral (Transverse Process) Spinal Fusion Model," <i>SPINE</i> (1995), pp. 2669-2683, vol. 20, Lippincott-Raven Publishers
	SANDHU, H.S., et al., "Effective Doses of Recombinant Human Bone Morphogenetic Protein-2 in Experimental Spinal Fusion," <i>SPINE</i> (1996), pp. 2115-2122, vol. 21, Lippincott Williams & Wilkins, Hagerstown, MD.
	SCHIMANDE, J.H., et al., "Experimental Spinal Fusion With Recombinant Human Bone Morphogenetic Protein-2," <i>SPINE</i> (1995), pp. 1326-1337, vol. 20, Lippincott Williams & Wilkins, Hagerstown, MD.
	SHEEHAN, J.P., et al., "Molecular Methods of Enhancing Lumbar Spine Fusion," <i>NEUROSURGERY</i> (1996), pp. 548-554, vol. 39
	STAELING-HAMPTON, K., et al., "Specificity of Bone Morphogenetic Protein-related Factors: Cell Fate and Gene Expression Changes in <i>Drosophila</i> Embryos Induced by <i>decapentaplegic</i> but not 60A," <i>CELL GROWTH & DIFFERENTIATION</i> (1994), pp. 585-593, vol. 5, American Association for Cancer Research, Philadelphia, PA.
	SUN, Y., et al., "Repair of large cranial defect using allogeneic cranial bone and bone morphogenetic protein," <i>PUBMED</i> 7600438 (1995), <i>Chinese Journal of Plastic Surgery and Burns</i> , Beijing, China.
	TORIUMI, D.M., et al., "Mandibular Reconstruction With a Recombinant Bone-Inducing Factor," <i>ARCH OTOLARYNGOL HEAD NECK SURG</i> (1991), pp. 1101-1112, vol. 117, American Medical Association, Chicago, IL.
	URIST, M.R., et al., "Regeneration of an enchondroma defect under the influence of an implant of human bone morphogenetic protein," <i>THE JOURNAL OF HAND SURGERY</i> (1986), pp. 417-419, Vol. 11A, Churchill Livingstone, Secaucus, NJ.
	VAN EEDEN, S.P. & RIPAMONTI, U., "Bone Differentiation in Porous Hydroxyapatite in Baboons Is Regulated by the Geometry of the Substratum: Implications for Reconstructive Craniofacial Surgery," <i>PLASTIC AND RECONSTRUCTIVE SURGERY</i> (1994), pp. 959-966, vol. 93, Lippincott Williams & Wilkins, Hagerstown, MD.
	VILJANEN, V.V., et al., "Partial Purification and Characterization of Bone Morphogenetic Protein from Bone Matrix of the Premature Moose (<i>Alces alces</i>): Degradation of Bone-Inducing Activity during Storage," (1996), pp. 447-460, vol. 28, European Surgical Research, Karger, Basel, Switzerland.
	VILJANEN, V.V., "Allogeneic and xenogeneic bone morphogenetic protein in skeletal reconstruction," (Academic Dissertation) UNIVERSITY OF TAMPERE (1997), Tampere, Finland
	WHARTON, K.A., et al., " <i>Drosophila</i> 60A gene, another transforming growth factor β family member, is closely related to human bone morphogenetic proteins," <i>PROC. NATL. ACAD. SCI. USA</i> (1991), pp. 9214-9218, vol. 88, National Academy of Sciences, Washington, DC.
	WOLFE M.W. & COOK, S.D., "Use of osteoinductive implants in the treatment of bone defects," <i>MEDICAL PROGRESS THROUGH TECHNOLOGY</i> (1994), pp. 155-168, vol. 20, Kluwer Academic, Boston, MA.

Substitute for forms 1449A/PTO & 1449B/PTO		ATTORNEY'S DKT NO. 032469-001	APPLICATION NO. 09/125,963
FOURTH INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Sam T. LINDHOLM <i>et al.</i>	
		FILING DATE November 24, 1998	GROUP 1647

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	YASKO, A.W., et al., "The Healing of Segmental Bone Defects, Induced by Recombinant Human Bone Morphogenetic Protein (rhBMP-2)," THE JOURNAL OF BONE AND JOINT SURGERY, (1992), pp. 639-670, vol. 74-A, American Ed. Journal of Bone and Joint Surgery, Boston, MA.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

• Substitute for form 1449A/PTO & 1449B/PTO

AUG 12 2004

FIRST
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 5

Complete If Known

Application Number	10/759,244
Filing Date	January 20, 2004
First Named Inventor	Sam T. Lindholm et al.
Examiner Name	

Attorney Docket Number 032469-007

O P E
DEC 19 2006

PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
DR	4,294,753		URIST	10-13-1981
	4,434,094		SEYEDIN et al.	02-28-1984
	4,455,256		URIST	06-19-1984
	4,563,350		NATHAN et al.	01-07-1986
	4,608,199		CAPLAN et al.	08-26-1986
	4,627,982		SEYEDIN et al.	12-09-1986
	4,681,763		NATHANSON et al.	07-21-1987
	4,737,578		EVANS et al.	04-12-1988
	4,761,471		URIST	08-02-1988
	4,774,228		SEYEDIN et al.	09-27-1988
	4,774,322		SEYEDIN et al.	09-27-1988
	4,789,732		URIST	12-06-1988
	4,798,885		MASON et al.	01-17-1989
	4,804,744		SEN	02-14-1989
	4,810,691		SEYEDIN et al.	03-07-1989
	4,843,063		SEYEDIN et al.	06-27-1989
	4,886,747		DERYNCK et al.	12-12-1989
	4,968,590		KUBERASAMPATH et al.	11-06-1990
	4,975,527		KOEZUKA et al.	12-04-1990
	5,011,691		OPPERMANN et al.	04-30-1991
	5,106,626		PARSONS et al.	04-21-1992
	5,108,753		KUBERASAMPATH et al.	04-28-1992
	5,187,076		WOZNEY et al.	02-16-1993
	5,393,739		BENTZ et al.	02-1995
	5,849,880		WOZNEY et al.	12-15-1998
	5,631,142		WANG et al.	05-20-1997
	6,190,880		ISRAEL et al.	02-20-2001
DR	6,207,813		WOZNEY et al.	03-27-2001
	6,245,889		WANG et al.	06-12-2001

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation	
					Yes	No
	WO 90/00205	PCT		01-14-1988		
	WO 90/00707	PCT		10-10-1989		
	WO 90/00700	PCT		10-19-1989		
	WO 90/00700	PCT		04-19-1990		
	WO 91/02744	PCT		03-07-1991		
	WO 91/05802	PCT		03-02-1991		
	WO 91/10047	PCT		11-20-1991		
DR	WO 94/26322	PCT		11-24-1994		
	WO 95/24474	PCT		08-14-1995		
	WO 95/33630	PCT		12-14-1995		
DR	41 30 546	DE		03-18-1993		

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

• Substitute for form 1448A/PTO & 1448B/PTO				Complete If Known	
FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>				Application Number	10/759,244
				Filing Date	January 20, 2004
				First Named Inventor	Sam T. Lindholm et al.
				Examiner Name	
Sheet	2	of	5	Attorney Docket Number	032469-007

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	<u>AAROF, M., et al., "Healing of experimentally created defects: a review." BERMUDEZ JOURNAL OF ORAL & MAXILLOFACIAL SURGERY (1995), pp. 312-318, vol. 33, Churchill Livingstone, Edinburgh, Scotland.</u>
DR	<u>AONO, AKI, et al., "Potent Ectopic Bone-Inducing Activity of Bone Morphogenetic Protein-4/7 Heterodimer," Biochemical and Biophysical Research Communication (1995), pp. 670-677, Academic Press, Inc.</u>
	<u>BODEN, S.D. et al., "Video-Assisted Lateral Intertransverse Process Arthrodesis," SPINE (1996), pp. 2689-2697, vol. 21, Lippincott Williams & Wilkins, Hagerstown, MD.</u>
	<u>BOSTROM, M., et al., "Use of Bone Morphogenetic Protein-2 in the Rabbit Ulnar Nonunion Model." CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (1995), pp. 272-282, no. 327, Lippincott Williams & Wilkins, Philadelphia, PA.</u>
	<u>CLEMENT, J.H., et al., "Bone morphogenetic protein 2 in the early development of <i>Xenopus laevis</i>." MECHANISMS OF DEVELOPMENT (1995), pp. 357-370, vol. 52, Elsevier Science, Limerick, Ireland.</u>
	<u>COOK, S.D., et al., "Recombinant Human Bone Morphogenetic Protein-7 Induces Healing in a Canine Long-Bone Segmental Defect Model," CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (1994), pp. 302-312, no. 301, J.B. Lippincott, Philadelphia, PA.</u>
	<u>COOK, S.D., et al., "The Effect of Recombinant Human Osteogenic Protein-1 on Healing of Large Segmental Bone Defects." THE JOURNAL OF BONE AND JOINT SURGERY, (1994), pp. 827-838, vol. 76-A, Amer. Vol., Boston, MA.</u>
	<u>COOK, S.D., et al., "In Vivo Evaluation of Recombinant Human Osteogenic Protein (rhOP-1) Implants As a Bone Graft Substitute for Spinal Fusions," SPINE (1994), pp. 1655-1663, vol. 19, Lippincott Williams & Wilkins, Hagerstown, MD.</u>
	<u>COOK, S.D., et al., "Effect of Recombinant Human Osteogenic Protein-1 on Healing of Segmental Defects in Non-Human Primates." BOSTON JOURNAL OF BONE AND JOINT SURGERY, (1995), pp. 734-750, American ed. 77(5), Boston, MA.</u>
	<u>COOK, S.D., et al., "Osteogenic Protein-1." CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (1996), pp. 29-38, no. 324, IR Lippincott, Philadelphia, PA.</u>
DR	<u>DAMIEN et al., "A Composite of Natural Coral, Collagen, Bone Protein and Basic Fibroblast Growth Factor Tested in a Rat Subcutaneous Model", Annales Chirurgiae et Gynaecologiae, Supplementum, (1993) 207, 117-28.</u>
DR	<u>DART et al., "Transforming growth factors from a human tumor cell: characterization of transforming growth factor beta and identification of high molecular weight transforming growth factor alpha. Biochemistry, (1985 Oct 8) 24 (21) 5925-31.</u>
	<u>DUDLEY, A.T., et al., "A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye," GENES & DEVELOPMENT (1995), pp. 2795-2807, Vol. 9, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.</u>
	<u>EHRNBERG, A., et al., "Comparison of Demineralized Allogeneic Bone Matrix Grafting (the Urist Procedure) and the Ilizarov Procedure in Large Diaphyseal Defects in Sheep," THE JOURNAL OF BONE AND JOINT SURGERY, (1993), pp. 436-447, vol. 75, Orthopaedic Research Society, American Ed. Journal of Bone and Joint Surgery, Boston, MA.</u>
	<u>EINHORN, T.A., et al., "The Healing of Segmental Bone Defects Induced by Demineralized Bone Matrix." THE JOURNAL OF BONE AND JOINT SURGERY (1984), pp. 274-279, vol. 66-A, The Journal of Bone and Joint Surgery, Boston, MA.</u>
	<u>FANG, J., et al., "Stimulation of new bone formation by direct transfer of osteogenic plasmid genes." Proc. Natl. Acad. Sci. (1996), pp. 5753-5758, vol. 93 (USA), National Academy of Sciences, Washington, DC.</u>
	<u>FISCHGRUND, J.S., et al., "Augmentation of Autograft Using rhBMP-2 and Different Carrier Media in the Canine Spinal Fusion Model," JOURNAL OF SPINAL DISORDERS (1995), pp. 467-472, Vol. 10, No. 6, Lippincott Williams & Wilkins, Hagerstown, MD.</u>
DR	<u>GAO, T.J., et al., "Microscopic evaluation of bone-implant contact between hydroxyapatite, bioactive glass and tricalcium phosphate implanted in sheep diaphyseal defects," BIOMATERIALS (1995), pp. 1175-1179, vol. 16, Oxford, England.</u>
	<u>GAO, T.J., et al., "Enhanced Healing of Segmental Tibial Defects in Sheep by a Composite Bone Substitute Comprised of Tricalcium Phosphate Cylinder, Bone Morphogenetic Protein and Type IV Collagen, JOURNAL OF BIOMEDICAL MATERIALS RESEARCH (1996), vol. 32, Interscience, Wiley, Hoboken, NJ.</u>
	<u>GAO, T.J., et al., "A coral composite implant containing bone morphogenetic protein repairs a segmental tibial defect in sheep: mechanics and immune assay," INTERNATIONAL ORTHOPAEDICS., German Ceramics Society, Cologne, Germany.</u>
	<u>GAO, T.J., et al., "Comparative Study on Potential of Natural Coral and Tricalcium Phosphate Cylinders in Healing a Segmental Diaphyseal Defect in Sheep," BIOCERAMICS, pp. 199-204, vol. 8, German Ceramics Society, Cologne, Germany.</u>
	<u>GAO, T.J., et al., "Composite of Bone Morphogenetic Protein (BMP) and Type IV Collagen, Coral-Derived Coral Hydroxyapatite and Tricalcium Phosphate Ceramics," INTERNATIONAL ORTHOPAEDICS (ACCEPTED), Springer Verlag, Berlin, Germany.</u>
	<u>GAO, T.J., et al., "Bone Inductive Potential and Dose-Dependent Response of Bovine Bone Morphogenetic Protein Combined with Type IV Collagen Carrier," ANNALES CHIRURGIE ET GYNAECOLOGIE (1993), pp. 77-84, vol. 207, University of Tampere, Finland, University of Helsinki, Finland.</u>
▼	<u>GAO, TIE-JUN, "Bioactive Delivery System for Extracted Bone Morphogenetic Proteins" (1996), Acta Universitatis Tamperensis, ser A, vol. 511, Academic Dissertation, Tampere, Finland</u>

Examiner Signature	Date Considered
--------------------	-----------------

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant."

Substitute for form 1449A/PTO & 1449B/PTO				Complete If Known	
FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>				Application Number	10759,244
				Filing Date	January 20, 2004
				First Named Inventor	Sam T. Lindholm et al.
				Examiner Name	
Sheet	3	of	5	Attorney Docket Number	032469-007

NON-PATENT LITERATURE DOCUMENTS					
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
GERHART, T.N., et al. "Healing Segmental Femoral Defects in Sheep Using Recombinant Human Bone Morphogenetic Protein." CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (1993), pp. 317-326, no. 293, J.B. Lippincott Company, Philadelphia, PA.					
DR	HARRIS, E.L.V., "Concentration of the Extract", Chapter 3, In: Protein Purification Methods: A Practical Approach, Harris et al. (Eds.), September, 1989, IRL Press, Oxford, UK, page(s) 125-130.				
HECKMAN, J.D., et al. "The Use of Bone Morphogenetic Protein in the Treatment of Non-Union in a Canine Model." THE JOURNAL OF BONE AND JOINT SURGERY (1991), pp. 750-764, vol. 73-A, The Journal of Bone and Joint Surgery, American Volume, Boston, MA.					
HELM, G.A., et al. "Utilization of type I collagen gel, demineralized bone matrix, and bone morphogenetic protein-2 to enhance autologous one lumbar spinal fusion." J. NEUROSURGERY. (1997), pp. 93-100, vol. 86, Charlottesville, VA.					
HOGAN, B.L.M., "Bone morphogenetic proteins: multifunctional regulators of vertebrate development." Currents & Development (1995), pp. 1580-1594, vol. 10, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.					
HOLLIGER, E.H., et al. "Morphology of the Lumbar Intertransverse Process Fusion Mass in the Rabbit Model: A Comparison Between Two Bone Graft Materials — RhBMP-2 and Autograft." JOURNAL OF SPINAL DISORDERS (1995), pp. 125-128, vol. 9, Lippincott Williams & Wilkins, Hagerstown, MD.					
HOLLINGER, J. & LEONG, K., "Poly(α-hydroxy acids): carriers for bone morphogenetic proteins." BIOMATERIALS (1996) pp. 187-194, vol. 17, Elsevier Science Limited, Butterworth-Heinemann, Oxford, England.					
HOTZ, G. & HARR, G., "Bone substitute with osteoinductive biomaterials - current and future clinical applications." INT. J. ORAL MAXILLOFAC. SURG. (1994), pp. 413-417, Vol. 23, Munksgaard, Copenhagen, Denmark					
HU, Y.Y., "Experimental studies on reconstituted xenograft and its clinical application." Chinese Journal of Surgery, Vol. 31, no. 12, pp. 709-713, Zhonghua yi xue hui, Wei ke xue hui, Beijing, China.					
JOHNSON, E.E. & URESTI, M.R., "Distal Metaphyseal Tibial Nonunions Associated with Significant Bowing Deformity and Cortical Bone Loss: Treatment with Human Bone Morphogenetic Protein (rh-BMP) and Internal Fixation." (1989), pp. 613-620, vol. 63, Nippon Seikeigeka Gakkai Zasshi, Japan.					
JOHNSON, E.E., et al., "Repair of Segmental Defects of the Tibia with Cancellous Bone Grafts Augmented with Human Bone Morphogenetic Protein," CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (1988), pp. 249-257, no. 236, JB Lippincott, Philadelphia, PA.					
JOHNSON, E.E., et al. "Bone Morphogenetic Protein Augmentation Grafting of Resistant Femoral Nonunions." CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (1988), pp. 257-265, no. 230, JB Lippincott, Philadelphia, PA.					
JOHNSON, E.E., et al. "Autogenous Cancellous Bone Grafts in Extensive Segmental Ulnar Defects in Dogs." CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (1989), pp. 254-265, no. 243, JB Lippincott, Philadelphia, PA.					
DR	JORTIKKA, LEENA, "Native Bone Morphogenetic Protein Purification and Action On Rat Skeletal Muscle Myoblast" (1998), Academic Dissertation Acta Universitatis Tamperensis 628, Tampere, Finland				
DR	JORTIKKA, LEENA, et al., "Partially Purified Reindeer (Rangifer Tarandus) Bone Morphogenetic Protein Has a High Bone-Forming Activity Compared With Some Other Artiodactyls," Clinical Orthopaedics and Related Research (1993), pp. 33-37, vol. 297, J. B. Lippincott Company				
DR	JORTIKKA et al., "Purification of monocomponent bovine bone morphogenetic protein in a water-soluble form", Annales Chirurgiae et Gynaecologiae, Supplementum, (1993) 207:25-30.				
KATO, F., "Experimental study of chemical spinal fusion in the rabbit by means of bone morphogenetic protein." (1990). PubMed 2380556, Nippon Seikeigeka Gakkai Zasshi, Japan.					
DR	KIRKER-HEAD, CARL A., et al., "Long-Term Healing of Bone Using Recombinant Human Bone Morphogenetic Protein 2." Clinical Orthopaedics and Related Research (1995), pp. 222-230, vol. 318, Lippincott-Raven Publishers				
KUBOKI, Y., et al. "Two Distinctive BMP-Carriers Induce Zonal Chondrogenesis and Membranous Ossification, Respectively: Geometrical Factors of Matrices for Cell-Differentiation." CONNECTIVE TISSUE RESEARCH (1995), pp. 219-226, vol. 32, Taylor & Francis, Philadelphia, PA.					
LEE, S.C., et al. "Healing of large segmental defects in rat femurs is aided by RhBMP-2 in PLGA matrix." JOURNAL OF BIOMATERIALS RESEARCH (1994), pp. 1149-1156, vol. 28, Wiley Interscience, Hoboken, NJ.					
LINDE, A. and HEDNER, E., "Recombinant Bone Morphogenetic Protein-2 Enhances Bone Healing, Guided by Osteopromotive e-PTFE Membranes: An Experimental Study in Rats." CALCIFIED TISSUE INT. (1995), pp. 549-553, vol. 56, Springer-Verlag, NY.					
LINDHOLM, T.S., et al. "Response of Bone Marrow Stroma Cells to Demineralized Cortical Bone Matrix in Experimental Spinal Fusion in Rabbits." CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (1988), pp. 296-302, no. 230, JB Lippincott, Philadelphia, PA.					
LINDHOLM, T.C., et al. "Bone Morphogenetic Proteins Regenerating Skull and Maxillo-Mandibular Defects." BONE MORPHOGENETIC PROTEINS (1995), pp. 149-155, FCG. Landes Company, Austin, TX.					
DR	LINDHOLM, T.S. and GAO, T.J., "Functional Carriers for Bone Morphogenetic Proteins." ANNALES CHIRURGIAE ET GYNAECOLOGIAE Supplementum, (1993), pp. 3-12, vol. 82, University of Helsinki, Helsinki, Finland.				
Examiner Signature	Date Considered				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

• Substitute for form 1449A/PTO & 1449B/PTO				Complete If Known	
FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>				Application Number	10/759,244
				Filing Date	January 20, 2004
				First Named Inventor	Sam T. Lindholm et al.
				Examiner Name	
Sheet	4	of	5	Attorney Docket Number	032469-007

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
DR	LINDHOLM, TOM C., "Calvarial Reconstruction With Implants Of: Hydroxyapatite, Autogenous Bone Marrow, Allogeneic Demineralized Bone Matrix and Bovine Bone Morphogenetic Protein," Dissertation, University of Tampere and University of Turku, Finland (1995), pp. 8-280, Laatupaino-Yhtiö Oy, Rauma, Finland
DR	LINDHOLM, T. SAM, M.D., Ph.D., "Tissue Engineering Intelligence Unit, Bone Morphogenetic Proteins: Biology, Biochemistry and Reconstructive Surgery" (1996), Chapters 3, 6, 12, 14, 15, 18, 19, R.G. Landes Company and Academic Press, Inc., Georgetown, Texas.
DR	LINDHOLM, T. S., et al., "Biological Activity of BMP to Type I and IV Collagen: A Preliminary Report," Department of Clinical Sciences, University of Tampere, pp. 45-50, Tampere, Finland.
	LOVELL, T.P., et al., "Augmentation of Spinal Fusion With Bone Morphogenetic Protein in Dogs," CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (1989), pp. 266-274, no. 243, JB Lippincott, Philadelphia, PA.
DR	MARTTINEN, A., et al., "Protein in a Water-Soluble Form," NEW TRENDS IN BONE GRAFTING (1991), pp. 40-43, Acta Universitatis Tamperensis, ser B vol 40, Tampere, Finland.
	MIYAMOTO, S. & TAKAOKA, K., "Bone Induction and Bone Repair by Composites of Bone Morphogenetic Protein and Biodegradable Synthetic Polymers," ANNALES CHIRURGIAE ET GYNAECOLOGIAE Supplement. 69-76, Vol. 82, University of Helsinki, Helsinki, Finland.
	MUSCHLER, G.F., et al., "Evaluation of Human Bone Morphogenetic Protein-2 in a Canine Spinal Fusion Model," CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (1994), pp. 229-240, no. 308, J.B. Lippincott Company, Philadelphia, PA.
	NILSSON, O.S., et al., "Bone Repair Induced by Bone Morphogenetic Protein in Ulnar Defects in Dogs," THE JOURNAL OF BONE AND JOINT SURGERY, British Volume, (1986), pp. 635-642, vol. 68-B, London, UK.
	ODA, S., et al., "Ectopic bone induction in recombinant human bone morphogenetic protein-2 (rhBMP-2) combined with biphasic calcium phosphate (BCP)," (1996), The Journal of Stomatological Society, Japan.
DR	OGAWA, et al., "Bovine bone activin enhances bone morphogenetic protein-induced ectopic bone formation", J. Biol Chem. (1992 Jul 15) 267 (20) 14233-7.
	ONO, I., et al., "Promotion of the Osteogenic Activity of Recombinant Human Bone Morphogenetic Protein by Prostaglandin E," BONE (1995), pp. 581-588, vol. 19, Elsevier Science Inc., NY.
DR	PAJAMÄKI, K.J.J., et al., "Bone Matrix in Rat Abdominal Muscle Pouch," University of Tampere, Tampere; Abo Akademi University, Turku, University of Turku, Turku, Finland, pp. 132-138.
DR	PAJAMÄKI, K.J.J., et al., "Fibronectin and Collagen Types I and III in Aggressive Granulomatous Lesions Surrounding Hip Implants," University of Tampere, Tampere, Finland, pp. 300-304.
	PANGANIBAN, G.E.F., et al., "Biochemical Characterization of the <i>Drosophila dpp</i> Protein, a Member of the Transforming Growth Factor β Family of Growth Factors," MOLECULAR AND CELLULAR BIOLOGY (1990), pp. 2669-2677, vol. 10, American Society for Microbiology, Washington, DC.
	PETIT, J.C. & RIPAMONTI, U., "Tissue Segregation Enhances Calvarial Osteogenesis in Adult Primates," THE JOURNAL OF CRANIOFACIAL SURGERY (1994), pp. 34-43, vol. 5, Little, Brown & Co., Boston, MA.
	RAGNI, P. & LINDHOLM T.S., "Interaction of Allogeneic Demineralized Bone Matrix and Porous Hydroxyapatite Bioceramics in Lumbar Interbody Fusion in Rabbits," CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (1991), pp. 292-299, no. 272, JB Lippincott, Philadelphia, PA.
	RAGNI, P., et al., "Spinal Fusion Induced by Porous Hydroxyapatite Blocks (HA)," pp. 433-444, Italian Journal of Orthopaedics & Traumatology, Bologna, Italy.
	RAGNI, P.C. & LINDHOLM, T.S., "Bone Formation and Static Changes in the Thoracic Spine at Uni- or Bilateral Experimental Spondylodesis with Demineralized Bone Matrix (DBM)," pp. 237-252, Italian Journal of Orthopaedics & Traumatology, Bologna, Italy.
	RILEY, F.H., et al., "Bone Morphogenetic Protein-2," CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (1995) pp. 39-45, no. 324, JB Lippincott, Philadelphia, PA.
	SAILER, H.F. & KOLB, E., "Application of purified bone morphogenetic protein (BMP) preparations in cranio-maxillo-facial surgery," JOURNAL OF CRANIO-MAXILLO-FACIAL SURGERY (1994), pp. 191-199, vol. 22, Churchill Livingstone, Edinburgh, Scotland.
	SAILER, H.F. & KOLB, E., "Application of purified bone morphogenetic protein (BMP) in cranio-maxillo-facial surgery," JOURNAL OF CRANIO-MAXILLO-FACIAL SURGERY (1994), pp. 2-11, vol. 22, Churchill Livingstone, Edinburgh, Scotland.
DR	SAMPATH, T.K. & REDDI, A.H., "Homology of bone-inductive proteins from human, monkey, bovine, and rat extracellular matrix," PROC. NATL. ACAD. SCI. USA (1983), pp. 6591-6595, vol. 80, National Academy of Sciences, Washington, DC.
	SAMPATH, T.K., et al., "Drosophila transforming growth factor β superfamily proteins induce endochondral bone formation in mammals," PROC. NATL. ACAD. SCI. USA (1993), pp. 6004-6008, vol. 90, National Academy of Sciences, Washington, DC.

Examiner Signature	Date Considered
--------------------	-----------------

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant."

FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>				Complete if Known	
Sheet		5	of	5	Attorney Docket Number
				10/759,244	
				January 20, 2004	
				Sam T. Lindholm et al.	
				Examiner Name	
				032469-007	

NON-PATENT LITERATURE DOCUMENTS


Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
DR	SAMPATH, T. KUBER, et al., "Bovine Osteogenic Protein Is Composed of Dimers of OP-1 and BMP-2A, Two Members of the Transforming Growth Factor- β Superfamily," <i>The Journal of Biological Chemistry</i> (1990), pp. 13198-13205, vol. 265, No. 22, The American Society for Biochemistry and Molecular Biology, Inc.
	SANDHU, H.S., et al., "Evaluation of rhBMP-2 With an OPLA Carrier in a Canine Posteriorlateral (Transverse Process) Spinal Fusion Model," <i>SPINE</i> (1995), pp. 2669-2683, vol. 20, Lippincott-Raven Publishers.
	SANDHU, H.S., et al., "Effective Doses of Recombinant Human Bone Morphogenetic Protein-2 in Experimental Spinal Fusion," <i>SPINE</i> (1995), pp. 2115-2122, vol. 21, Lippincott Williams & Wilkins, Hagerstown, MD.
	SCHIMANDLE, J.H., et al., "Experimental Spinal Fusion With Recombinant Human Bone Morphogenetic Protein-2," <i>SPINE</i> (1995), pp. 1326-1337, vol. 20, Lippincott Williams & Wilkins, Hagerstown, MD.
	SHEEHAN, J.P., et al., "Molecular Methods of Enhancing Lumbar Spine Fusion," <i>NEUROSURGERY</i> (1996), pp. 548-554, vol. 39.
	STAEHLING-HAMPTON, K., et al., "Specificity of Bone Morphogenetic Protein-related Factors: Cell Fate and Gene Expression Changes in <i>Drosophila</i> Embryos Induced by <i>decapentaplegic</i> but not <i>SOA</i> ," <i>CELL GROWTH & DIFFERENTIATION</i> (1994), pp. 585-593, vol. 5, American Association for Cancer Research, Philadelphia, PA.
	SUN, Y., et al., "Repair of large cranial defect using allogenous cranial bone and bone morphogenetic protein." PUBMED 7600438 (1995), Chinese Journal of Plastic Surgery and Burns, Beijing, China.
	TORIUMI, D.M., et al., "Mandibular Reconstruction With a Recombinant Bone-Inducing Factor," <i>ARCH OTOLARYNGOL HEAD NECK SURG</i> (1991), pp. 1101-1112, vol. 117, American Medical Association, Chicago, IL.
	URIST, M.R., et al., "Regeneration of an enchondroma defect under the influence of an implant of human bone morphogenetic protein," <i>THE JOURNAL OF HAND SURGERY</i> (1985), pp. 417-419, Vol. 11A, Churchill Livingstone, Secaucus, NJ.
DR	URIST, M. R., et al., "Native Bone Morphogenetic Protein," University of Tampere Editorial Board (1992), pp. 27-39, Tampere, Finland.
DR	URIST, M. R., et al., "Purification of bovine bone morphogenetic protein by hydroxyapatite chromatography," <i>Proc. Natl. Acad. Sci. USA</i> (1984), pp. 371-375, vol. 81.
DR	URIST, MARSHALL R., "The search for and the discovery of bone morphogenetic protein (BMP)," <i>Bone Grafts, Derivatives and Substitutes</i> (1994), Chapter 17, pp. 315-362, Butterworth-Heinemann Ltd., Jordan Hill, Oxford, U.K.
	VAN EEDEN, S.P. & RIPAMONTI, U., "Bone Differentiation in Porous Hydroxyapatite in Baboons Is Regulated by the Geometry of the Substratum: Implications for Reconstructive Craniofacial Surgery," <i>PLASTIC AND RECONSTRUCTIVE SURGERY</i> (1994), pp. 959-966, vol. 93, Lippincott Williams & Wilkins, Hagerstown, MD.
DR	VILJANEN, V.V., et al., "Partial Purification and Characterization of Bone Morphogenetic Protein from Bone Matrix of the Premature Moose (<i>Alces alces</i>): Degradation of Bone-Inducing Activity during Storage," (1996), pp. 447-460, vol. 28, European Surgical Research, Karger, Basel, Switzerland.
	VILJANEN, V.V., "Allogeneic and xenogeneic bone morphogenetic protein in skeletal reconstruction," (Academic Dissertation) UNIVERSITY OF TAMPERE (1997), Tampere, Finland.
DR	VILJANEN, V. V., et al., "Xenogeneic moose (<i>Alces alces</i>) bone morphogenetic protein (mBMP)-induced repair of critical-size skull defects in sheep," <i>International Journal of Oral Maxillofacial Surgery</i> (1996), pp. 217-222, vol. 25, University of Tampere, Tampere and University of Helsinki, Helsinki, Finland.
DR	VILJANEN, V. V., et al., "List of References On Demineralized Bone Matrix Induced Osteogenesis and Research of Bone Morphogenetic Proteins During the Period From 1951 Through 1995," <i>Tissue Engineering Intelligence Unit, Bone Morphogenetic Proteins: Biology, Biochemistry and Reconstructive Surgery</i> (1996), Appendix pp. 242-308, R. G. Land
	WHARTON, K.A., et al., "Drosophila SOA gene, another transforming growth factor- β family member, is closely related to human bone morphogenetic proteins," <i>PROC. NATL. ACAD. SCI. USA</i> (1991), pp. 9214-9218, vol. 88, National Academy of Sciences, Washington, DC.
	WOLFF MW & COOK S.D., "Use of osteoinductive implants in the treatment of bone defects," <i>Medical Progress through TECHNOLOGY</i> (1994), pp. 155-168, vol. 20, Kluwer Academic, Boston, MA.
	YASKO, A.W., et al., "The Healing of Segmental Bone Defects, Induced by Recombinant Human Bone Morphogenetic Protein (rhBMP-2)," <i>The Journal of Bone and Joint Surgery</i> , (1992), pp. 639-670, vol. 74-A, American Ed. <i>Journal of Bone and Joint Surgery</i> , Boston, MA.

Examiner Signature	/David Romeo/ (10/01/2006)	Date Considered
--------------------	----------------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Inventor: LINDHOLM et al.
Docket No.: 032469-001 (Borenius & Co.)

Appln. No. 09/125,963 Filing Date: November 24, 1998
Atty. DHY,co Date: September 26, 2003




The following was/were received in the U.S. Patent and Trademark Office on the date stamped hereon:

21

- Amendment or Response
- Preliminary Amendment
- Reply Transmittal Letter
- Petition for _ Month Extension of Time
- Submission of Formal Drawings w/_ sheet(s) of drawings (Figs. 1-1)
- Request for Approval of Drawing Changes w/_ sheet(s) of red ink drawings
- Notice of Appeal
- Brief for Appellant
- Request for Oral Hearing
- Reply Brief
- Response to Restriction Requirement or Election of Species
- Terminal Disclaimer
- Certificate Under 37 C.F.R. § 3.73(b)
- Transmittal Letter for Missing Parts of Application
- Executed Declaration/Power of Attorney
- Assignment/Acknowledgment Recordation Form Cover Sheet (PTO-1595)
- Claim for Convention Priority w/_ certified copy(s)
- Information Disclosure Statement w/73 document(s)
- Information Disclosure Citation (PTO-1449)
- Information Disclosure Statement Transmittal Letter
- Request for Corrected Notice of Recordation of Assignment w/copy of Notice
- Request for Continued Examination
- Check for \$_ is enclosed
- Check for \$_ is enclosed
- Charge \$_ to Deposit Account
- Issue Fee Transmittal
- Payment of Issue Fee and Authorization to charge Deposit Account
- Request for Refund
- Status Inquiry
- Request for Corrected Filing Receipt w/copy of Official Filing Receipt
- □

(05/03)



3


SEP 26 2003 JC34
PATENT & TRADEMARK OFFICE


52



UNITED STATES PATENT AND TRADEMARK OFFICE



1032469-000007

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

21839 7590 10/03/2006

BUCHANAN, INGERSOLL & ROONEY PC
POST OFFICE BOX 1404
ALEXANDRIA, VA 22313-1404

~~NOTICE OF ALLOWANCE AND FEE(S) DUE~~

BUCHANAN, INGERSOLL P		EXAMINER
		ROMEO, DAVID S
ART UNIT	PAPER NUMBER	
OCT - 4 2006		
DATE MAILED: 10/03/2006		
DOCKETED 10-5007M.		

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/759,244	01/20/2004	Sam T. Lindholm	032469-007	7086

TITLE OF INVENTION: OSTEOGENIC DEVICE AND A METHOD FOR PREPARING THE DEVICE

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES	\$700	\$300	\$0	\$1000	01/03/2007

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: **Mail Stop ISSUE FEE**
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

21839 7590 10/03/2006

BUCHANAN, INGERSOLL & ROONEY PC
 POST OFFICE BOX 1404
 ALEXANDRIA, VA 22313-1404



Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission
 I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

	(Depositor's name)
	(Signature)
	(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/759,244	01/20/2004	Sam T. Lindholm	032469-007	7086

TITLE OF INVENTION: OSTEOGENIC DEVICE AND A METHOD FOR PREPARING THE DEVICE

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES	\$700	\$300	\$0	\$1000	01/03/2007

EXAMINER	ART UNIT	CLASS-SUBCLASS
ROMEO, DAVID S	1647	530-417000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

"Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.

2. For printing on the patent front page, list

(1) the names of up to 3 registered patent attorneys or agents OR, alternatively,

(2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent): Individual Corporation or other private group entity Government

4a. The following fee(s) are submitted:

Issue Fee
 Publication Fee (No small entity discount permitted)
 Advance Order - # of Copies _____

4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)

A check is enclosed.
 Payment by credit card. Form PTO-2038 is attached.
 The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number _____ (enclose an extra copy of this form).

5. Change in Entity Status (from status indicated above)

a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.
 b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature _____ Date _____

Typed or printed name _____ Registration No. _____

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



UNITED STATES PATENT AND TRADEMARK OFFICE

DEC 19 2006

IAPB7
PATENT & TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/759,244	01/20/2004	Sam T. Lindholm	032469-007	7086

21839 7590 10/03/2006
BUCHANAN, INGERSOLL & ROONEY PC
POST OFFICE BOX 1404
ALEXANDRIA, VA 22313-1404

EXAMINER	
ROMEO, DAVID S	
ART UNIT	PAPER NUMBER

1647
DATE MAILED: 10/03/2006


Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 562 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 562 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.



Notice of Allowability

Application No.	Applicant(s)
10/759,244	LINDHOLM ET AL.
Examiner	Art Unit
David S. Romeo	1647

~~This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.~~
The MAILING DATE of this communication appears on the cover sheet with the correspondence address--
unless being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to 01/20/2004.
2. The allowed claim(s) is/are 16 and 17.
3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. §.119(a)-(d) or (f).
 - a) All
 - b) Some*
 - c) None of the:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).


* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
1) hereto or 2) to Paper No./Mail Date _____.
 - (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)
2. Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date 0804
4. Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. Notice of Informal Patent Application
6. Interview Summary (PTO-413),
Paper No./Mail Date _____.
7. Examiner's Amendment/Comment
8. Examiner's Statement of Reasons for Allowance
9. Other See Continuation Sheet.


David S. Romeo
Primary Examiner
Art Unit: 1647

Continuation of Attachment(s) 9. Other: The information disclosure statement filed 08/02/2004 fails to fully comply with 37 CFR 1.98(a)(2), which requires a legible copy of each cited foreign patent document; each non-patent literature publication or that portion which caused it to be listed; and all other information or that portion which caused it to be listed. The non-complying information not being considered.. It is acknowledged that applicants indicate that the listed references were made of record in parent U. S. Application No. 09/125,963. However, inspection of the parent applications has revealed that the indicated non-complying references are not of record in the parent application. Copies of the non-complying references have not been provided.